TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of seropositive (i.e., presence of RF and/or anti-CCP antibodies) rheumatoid arthritis (RA) according to the ACR/EULAR 2010 criteria within 24 months.~2. No previous treatment with disease modifying anti-rheumatic drugs (DMARDs). History of prednisone use is allowed but should have been discontinued 2 weeks before baseline measurement.~3. Active disease with ≥2 painful and ≥2 swollen joints in 66/68 joints and CRP ≥2.0 mg/L~4. Aged 18-80 years~5. The subject has given written consent to participate in the study.~Exclusion Criteria:~1. Current active inflammatory joint disease other than RA.~2. Significant and/or uncontrolled cardiac, pulmonary disease, nervous system, renal, hepatic, endocrine or gastrointestinal disorders or severe RA which in the investigator's opinion would preclude patient participation.~3. Malignancy within the past 5 years, except for successfully treated cervical carcinoma in situ, basal cell and squamous cell carcinoma of the skin, with no evidence of recurrence or metastatic disease for at least 3 years.~4. Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection.~5. Pregnant or lactating women.~   For subjects in part II the following exclusion criteria also apply:~6. Women of childbearing potential not willing or able to use highly effective methods of birth control per ICH M3 (R2) for 28 days prior and 3 months after end of study.~7. Active infection (excluding fungal infections of nail beds) requiring i.v. anti-infectives within 4 weeks, or oral anti-infectives within 2 weeks prior to baseline.~8. Positive tests for hepatitis B (HBsAg or HBV DNA),hepatitis C serology or SARS-CoV2~9. History of herpes zoster infection during last 10 years.~10. History or risk of venous thromboembolism or diverticulitis.~11. Positive tuberculosis history and/or positive Quantiferon test.~12. Hemoglobin \<90 g/L.~13. Absolute neutrophil count \< 1500 cells/uL.~14. ASAT or ALAT \>2.0 times the upper limit of normal.~15. High or very high risk (≥ 5%) of cardiovascular death within 10 years by SCOREx1,5.~16. Multiple incidental solid/subsolid lung nodules of size ≥6 mm, single incidental solid lung nodules ≥8 mm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: EXPERIMENTAL): Oral tablet tofacitinib 5 mg BID for 48 weeks
- Methotrexate (Type: ACTIVE_COMPARATOR): Oral tablet methotrexate 2.5 mg: 8 tablets in one dose (=20 mg) once weekly for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects aged 18 or older, male or female of any race with the diagnosis of NDPH meeting International Classification of Headache Disorders (ICHD-2) criteria will be included in the study. The criteria is as follows:~A. Persistent headache fulfilling criteria B and C B. Distinct and clearly remembered onset, with pain becoming continuous and unremitting within 24 hours C. Present for \>3 months D. Not better accounted for by another ICHD-3 diagnosis~Exclusion Criteria:~1. Those with relevant physical or psychological illness, particularly conditions that might put them at risk if exposed to OnabotulinumtoxinA (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other neuromuscular disease).~2. Diagnosis of other primary/secondary headache disorder.~3. Psychiatric disorders that could interfere with study participation.~4. Subjects who abuse drugs, including headache treatments and alcohol (DSM IV criteria).~5. Those allergic to compounds similar to the study medication.~6. Those who are pregnant or breastfeeding, or who do not use adequate contraceptive methods.~7. Those who have had any prior exposure to any botulinum toxin serotype.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of IPF confirmed by lung biopsy or by characteristic pattern on high resolution computed tomogram (HRCT)~* No identifiable cause of lung fibrosis~* PR not received in the past year~* Ability to walk~Exclusion Criteria:~* History of unstable angina~* Deterioration cardiac or neurological disease~* Pregnancy or lactation~* Degenerative arthritis or other limitation to mobility~* PR in the past 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: OTHER): This project is being withdrawn. No revisions to ARM is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Surgical Decompression Versus Conservative Treatment in Incomplete Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- all patients with a history of a traumatic event to the cervical spine fulfilling the criteria of incomplete cervical spinal cord lesion. -~Exclusion Criteria:~* cognitive impairments~* a preexistent neurologic deficit of arms and/or legs~* psychiatric illness~* significant comorbidity interfering with the indication to perform surgery or not~* use of anticoagulating drugs~* addiction to drugs or alcohol (more than five units daily)~* not speaking Dutch language fluently~* not willing to participate~* participating in another trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- surgical decompression (Type: EXPERIMENTAL): surgical decompression within 24 hours post-injury
- Conservative treatment (Type: ACTIVE_COMPARATOR): Normal conservative treatment without surgical intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate to severe stable chronic plaque psoriasis for at least 6 months, with or without psoriatic arthritis~* Affected body surface area (BSA) greater than or equal to 15%~* Physician's Global Assessment (PGA) score of 3 or more~* Female subjects of non-childbearing potential or postmenopausal for at least 1 year. Male subjects must agree to use effective method of birth control~* Body Mass Index (BMI) less than or equal to 38.0 kg/m2~Exclusion Criteria:~* Concomitant anti-psoriatic treatment~* Infectious disease requiring systemic anti-infectious treatment within the 2 weeks prior to administration of trial drug~* Known history of Human Immunodeficiency Virus (HIV)~* Hepatitis B and/or C (determined by test)~* Live virus or bacteria vaccines within the last month before drug administration~* Known active herpes/herpes zoster/cold sores~* Kidney insufficiency~* Liver insufficiency~* Lymphoproliferative disease~* History or signs of malignancy within the last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Anti-IL-20 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Fetal Tracheal Balloon Study in Diaphragmatic Hernia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton pregnancies~* Isolated congenital diaphragmatic hernia~* Normal karyotype (amniocentesis)~* Initial diagnosis before 26 weeks gestation~* Competent cervix~* Severity of CDH: lung-to-head ratio (LHR) ≤0.8 at 22-26 weeks gestation~* Liver herniation in the chest~* Informed consent~Exclusion Criteria:~* Preterm labor, premature rupture of membranes or amniotic leak~* Significant maternal morbidity~* Minor (\<18 years)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Detachable balloon (Type: EXPERIMENTAL): Intervention: Fetuses treated with endoscopic tracheal occlusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Protective Role of Inhaled Steroids for Covid-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criera :~* Patient ≥ 18 years old and ≤ 75 years old~* Laboratory proved infection by COVID-19 by RT-PCR on a respiratory biological sample within 2 days~* Hospitalization is required according to current local recommendations~* Patient affiliated to a social security regime~* Patient able to give free, informed and written consent~Exclusion criteria :~* Oxygen flow rate \>8l/min at inclusion~* Current treatment with any inhaled steroid (any other form of steroid administration does not exclude the patient)~* Intensive care unit is required for the patient (based on investigator judgement)~* Patient with cognitive impairment which do not guarantee proper use of the treatment by the patient himself~* Pregnant (positive β-HCG at inclusion) or breastfeeding women~* Participation in another interventional drug study involving human participants and concerning COVID-19 infection or being in the exclusion period of a previous study involving human participants~* Contraindications to the treatments (history of hypersensitivity)~* Patient admitted for isolation, for social reason or due to comorbidities without gravity sign~* Long-term patient treated with digitalis, disopyramide, procainamide or phenothiazine that could lengthen the QT space

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1: Usual practice (Type: ACTIVE_COMPARATOR): arm will be follow during 30 days
- 2: Usual practice + SYMBICORT RAPIHALER (Type: EXPERIMENTAL): Usual practice + SYMBICORT RAPIHALER 200/6 µg ( 2 puffs bid during 30 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: User Testing of the Evivo Screening Test

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infants aged 0-6 months.~* Generally healthy infants.~Exclusion Criteria:~* Infants should not have an acute infection.~* Not intended for use with stool containing meconium.~* Infants with jaundice should not be tested until it has resolved.~* This test should not be used for infants with carbohydrate malabsorption syndrome, which may present with one or more of the following persistent signs: abnormally foul-smelling, mucus-containing, and/or green frothy stools.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- Infants less than 6 months of age (Type: OTHER): The Evivo Infant Gut Bifidobacterium Screening Test study is a single-group interventional study of 600 female and male infants who are less than 6 months of age and generally healthy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Cryosurgery in Treating Patients With Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Biopsy-proven soft tissue sarcoma (STS) of the extremity Review by Pathology Department of the University of Southern California CT or MRI required prior to biopsy Disease in one of the following categories: High-grade tumor Low-grade tumor at high risk for local recurrence, i.e.: Adjacent to bone or vital neurovascular structures and able to be removed with a minimal surgical margin (i.e., plane of dissection goes through reactive zone of tumor) Lesion more than 5 cm in diameter The following tumors exclude: Primary sarcoma of the bone Metastatic carcinoma STS of the head and neck Visceral STS, e.g., breast, uterus, spermatic cord, mediastinum chest wall STS of the pelvis or retroperitoneum~PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Hematopoietic: WBC at least 3,000 Platelets at least 75,000 Hemoglobin at least 9 g/Dl Hepatic: Bilirubin no greater than 1.5 mg/dL AST/ALT no greater than 2.5 times normal Renal: Not specified Other: No concurrent disease that renders patient medically or psychologically unable to tolerate treatment~PRIOR CONCURRENT THERAPY: At least 30 days since therapy for sarcoma

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Pain, Couples, & Physical Activity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: FAMILY_BASED
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Currently in a relationship for at least 1 year or more.~* Both individuals in the relationship are 18 years or older.~* One individual in the relationship identifies as having a chronic musculoskeletal pain condition.~Exclusion Criteria:~* One or both individuals are 17 years old or younger.~* Neither individual identifies as having a chronic musculoskeletal pain condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Individuals with Chronic Pain (Type: None): Individuals who identify as having a chronic musculoskeletal pain condition.
- Partners (Type: None): Partners (e.g., life partner, spouse, or significant other) of the individual with the chronic musculoskeletal pain condition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsing MS according to the revised 2005 McDonald criteria~* Has shown disease activity defined by 1 or more MS attack within the last year which has been documented in prior medical notes and or the presence of active lesions on historical scans being either (based on radiology report or investigator review of MRI):~* Gd-enhancing on any scan obtained in the last year, or~* new T2 lesions between two scans both obtained within the last year~* A minimum total of 9 T2 lesions reported on a recent MRI obtained within 1 month prior to the screening visit~* Baseline EDSS score 0 - 5.5~* Has refused to be treated with approved disease modifying therapies available for MS, for any reason and once the investigator has fully informed the patient about the related benefits and potential adverse events associated with such treatments. Also, patients for whom such treatments have proved to be intolerable~Exclusion Criteria:~* Has experienced an MS relapse or received systemic corticosteroids or adrenocorticotropic hormone (ACTH) in the previous 1 month~* Has a secondary progressive (SPMS), progressive relapsing (PRMS), or primary progressive MS (PPMS).~* Has received any of the following agents to treat MS (approved or unapproved):~* Within the previous 3 months: interferon beta, glatiramer acetate, intravenous immunoglobulin or plasmapheresis~* Within the previous 12 months: natalizumab, daclizumab, cytapheresis, azathioprine, cladribine, cyclophosphamide, methotrexate, mitoxantrone, mycophenolate, pixantrone, sirolimus, tacrolimus, or other agents typically used to prevent transplant rejection or as cancer chemotherapy, excluding hormonal treatments~* Ever having received: stem cell or bone marrow transplant, total lymphoid irradiation, vaccine therapy for MS, or monoclonal antibodies whose effects may be longer than 1 year (such as alemtuzumab or rituximab)~* Within the previous 3 months: any other agents given for the non-symptomatic treatment of MS which are not included above, including over-the-counter, herbal and nutritional supplements. However, if the agent is being taken primarily to treat another medical condition, then it is allowed as long as the dose is unchanged within the previous 3 months and is unlikely to change before week 24.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BGC20-0134 (Pleneva TM) (Type: EXPERIMENTAL): Structured lipid
- Placebo control (Type: PLACEBO_COMPARATOR): Placebo - dummy pill

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rhythmic Entrainment in Bilingual Speakers With Dysarthria

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of idiopathic Parkinson's disease (4) or dysarthria secondary to ataxia (4) or healthy (4)~* monolingual speaker of American English (6) or native speaker of Spanish who speaks English with a Spanish accent (6)~* age 21 or older~Exclusion Criteria:~* Cognitive impairment that prevents participation in the therapy~* Fluent speakers of languages other than English or Spanish~* younger than 21 years

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Gestures (Type: EXPERIMENTAL): Use of hand gestures to improve speech rhythm and speech production
- Auditory (Type: EXPERIMENTAL): Use of auditory cues to improve speech rhythm and speech production

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: SCO2T (Servo vs. Servo)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants born at less than 30 weeks gestation~2. Infants greater than 48 hours of age~3. Infants who are receiving supplementary oxygen~4. Person with parental responsibility able to give consent~Exclusion Criteria:~1. Congenital anomalies that would prevent targeting SpO2 to 90-95% (e.g. cardiac defects)~2. Clinical condition of an infant would impair accurateTcPO2 measurement (e.g. impaired perfusion or requirement of inotropic or vasopressor support)

- Gender: ALL
- Minimum Age: 2 Days
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Servo control - Leoni plus CLAC (Type: EXPERIMENTAL): Automated control of oxygen. The oxygen saturation target range will be set to 90-95% as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets.
- Servo control - IntellO2 Precision Flow, Vapotherm (Type: ACTIVE_COMPARATOR): Automated control of oxygen. The oxygen saturation target range will be set to 90-95% (set to maintain an integral value of 93%) as per standard practice.~Automated oxygen control can be overridden by manual adjustment of oxygen at any time if this is considered necessary to optimise control of oxygenation according to current clinical targets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues